Similar to our research, most studies described abnormal expression of FADS2 in many cancers, including liver, lung, breast, esophagus, leukemia, melanoma and other malignant tumors, and showed a significant correlation between FADS2 expression and tumor proliferation, cell migration and invasion, angiogenesis, resistance to radiotherapy, histologic grade, metastasis to lymph nodes, clinical stage and prognosis [30]. This evidence concerns the gene FADS2 and leukemia.